Tuesday, October 27, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· July 13, 2026

Brown-Forman Announces President & CEO Lawson Whiting to Retire

View original at finance.yahoo.com
Brown-Forman Announces President & CEO Lawson Whiting to Retire Board Initiates Search Process for Successor; Company Reiterates Fiscal 2027 Outlook LOUISVILLE, Ky., July 13, 2026--(BUSINESS WIRE)--Brown-Forman Corporation (NYSE: BFA, BFB) today announced Lawson Whiting has decided to retire from his role as President…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Stated the Board appreciates Whiting giving ample notice, enabling a robust internal and external talent review; expressed confidence in the business and long-term stakeholder value creation, and noted Whiting will continue advancing strategic priorities including geographic expansion, brand building, and operational efficiency during the succession process.

    60% confidence
  • Thanked Lawson Whiting for nearly 30 years of dedication to Brown-Forman, describing him as a steadfast steward of the founder's vision who built the most premium portfolio in the industry; noted Jack Daniel's international expansion, Woodford Reserve's rise to leading super-premium American whiskey, and Old Forester tripling in volume and increasing net sales six-fold over the last decade.

    60% confidence
  • Described leading Brown-Forman as the privilege of a lifetime, credited his tenure to the people he worked with, said the company enters this transition from a position of strength with principled leadership, iconic brands, and deep talent, and expressed confidence the succession process will find the right next leader.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com